Comparative Effectiveness of Luliconazole, Sertaconazole, and Terbinafine for Tinea Corporis and Tinea Cruris: A Systematic Review
DOI:
10.29303/jbt.v26i3.13063Published:
2026-08-19Downloads
Abstract
Dermatophytosis (tinea corporis and tinea cruris) is a superficial fungal infection with a high prevalence in tropical regions. The WHO has reported cases of resistance to antifungal treatments. Topical antifungals from the allylamine (terbinafine) and azole (sertaconazole and luliconazole) classes are widely used; however, evidence regarding their comparative head-to-head effectiveness is inconsistent and has not yet been systematically synthesized with rigorous methodological quality assessment. This study aimed to evaluate and compare the clinical effectiveness, mycological cure rates, cost-effectiveness, and safety of topical terbinafine, sertaconazole, and luliconazole for tinea corporis and tinea cruris through a systematic review. A literature search was conducted using Publish or Perish across Google Scholar (n=200) and PubMed (n=16), yielding 216 articles. Following deduplication via Covidence (17 duplicates), title/abstract screening, and full-text review, nine studies met the final eligibility criteria. Methodological quality was assessed using the JBI Critical Appraisal Checklist for RCTs (13 items); six studies scoring >50% were included in the narrative synthesis. Results showed that comparisons between sertaconazole and terbinafine (four studies) consistently demonstrated equivalent effectiveness, although one high-quality study reported sertaconazole to be superior in terms of rapid relief from pruritus and achieving mycological cure. In one study of moderate quality, luliconazole demonstrated a significantly greater reduction in symptom scores compared to terbinafine. Sertaconazole showed higher clinical effectiveness than luliconazole, yet luliconazole was superior in terms of cost-effectiveness in one moderate-quality study. All three drugs were reported to be safe and well-tolerated. In conclusion, the three antifungal agents demonstrate generally comparable effectiveness in the management of tinea corporis and tinea cruris infections, although sertaconazole and luliconazole tend to outperform terbinafine in certain parameters across some studies.
Keywords:
Luliconazole Sertaconazole Systematic review Terbinafine Tinea corporis Tinea crurisReferences
Amudha, G., Bharathi, M. K., & Mukund, P. R. (2025). Comparative evaluation of clinical efficacy of topical luliconazole 1% versus terbinafine 1% in Tinea corporis and Tinea cruris: A clinical scoring analysis. International Journal of Life Sciences Biotechnology and Pharma Research, 14(1), 1000–1003.
Baghi, N., Shokohi, T., Badali, H., Makimura, K., Rezaei-Matehkolaei, A., Abdollahi, M., Didehdar, M., Haghani, I., & Abastabar, M. (2016). In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Medical Mycology, 54(7), 757–763. https://doi.org/10.1093/mmy/myw016
Blanchard, G., Amarov, B., Fratti, M., Salamin, K., Bontems, O., Chang, Y.-T., Sabou, A. M., Künzle, N., Monod, M., & Guenova, E. (2023). Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections. Journal of the European Academy of Dermatology and Venereology, 37(10), 2080–2089. https://doi.org/10.1111/jdv.19253
Borgohain, M., Elango, P., & Chellathai, D. (2016). Comparative study of the efficacy and safety of topical sertaconazole versus topical terbinafine in the treatment of dermatophytoses in a tertiary care centre. International Journal of Basic & Clinical Pharmacology, 5(3), 855–861. 10.18203/2319-2003.ijbcp20161534
Bortoluzzi, P., Prigitano, A., Sechi, A., et al. (2023). Report of terbinafine resistant Trichophyton spp. in Italy: Clinical presentations, molecular identification, antifungal susceptibility testing and mutations in the squalene epoxidase gene. Mycoses, 66(8), 680–687. https://doi.org/10.1111/myc.13597
Chatterjee, D., Ghosh, S. K., Sen, S., Sarkar, S., Hazra, A., & De, R. (2016). Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. Indian Journal of Pharmacology, 48(6), 659–664. 10.4103/0253-7613.194850
Dakhale, G. N., Gupta, A. V., Mukhi, J. I., & Kalikar, M. V. (2021). Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study. Perspectives in Clinical Research, 12(4), 223–228. 10.4103/picr.PICR_24_19
De Paepe, R., Normand, A.-C., Uhrlaß, S., Nenoff, P., Piarroux, R., & Packeu, A. (2024). Resistance profile, terbinafine resistance screening and MALDI-TOF MS identification of the emerging pathogen Trichophyton indotineae. Mycopathologia. https://doi.org/10.1007/s11046-024-00835-4
Ebert, A., Monod, M., et al. (2024). Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01407-24
Gupta, A. K., Cooper, E. A., Wang, T., Ravi, S. P., Lincoln, S. A., Piguet, V., ... & Bakotic, W. L. (2023). Detection of squalene epoxidase mutations in United States patients with onychomycosis: implications for management. Journal of Investigative Dermatology, 143(12), 2476-2483. https://doi.org/10.1016/j.jid.2023.04.032
Gupta, A. K., Foley, K. A., & Versteeg, S. G. (2017). New antifungal agents and new formulations against dermatophytes. Mycoses, 60(3), 127–141. https://doi.org/10.1007/s11046-016-0045-0.
Jerajani, H. R., Janaki, C., Kumar, S., & Phiske, M. (2013). Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine (1%) cream versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian Journal of Dermatology, 58(1), 34–38. https://doi.org/10.4103/0019-5154.105284
Kang, S., Amagai, M., Bruckner, A. L., Enk, A. H., Margolis, D. J., & McMichael, A. J. (Eds.). (2019). Fitzpatrick's dermatology (9th ed.). McGraw-Hill Education.
Khare, S., Nagar, R., & Saify, B. (2016). Comparative assessment of the effectiveness and safety of sertaconazole cream versus terbinafine cream versus luliconazole versus clotrimazole cream in patients with tinea cruris. International Journal of Contemporary Medical Research, 3(1), 191–195.
Mechidi, P., Holien, J., Grando, D., Huynh, T., & Lawrie, A. C. (2024). New sources of resistance to terbinafine revealed and squalene epoxidase modelled in the dermatophyte fungus Trichophyton interdigitale from Australia. Mycoses, 67, e13795. https://doi.org/10.1111/myc.13795
Meghana, D., Kamath, L., & Revathi, T. N. (2021). Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris: A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 11(1), 13–16. 10.5455/njppp.2021.10.07180202022082020
Mohammadi, L. Z., Shams-Ghahfarokhi, M., Salehi, Z., & Razzaghi-Abyaneh, M. (2024). Increased terbinafine resistance among clinical genotypes of Trichophyton mentagrophytes/T. interdigitale species complex harboring squalene epoxidase gene mutations. Journal of Medical Mycology, 34(3), 101495. https://doi.org/10.1016/j.mycmed.2024.101495
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Rengasamy, M., Shenoy, M. M., Dogra, S., Asokan, N., Khurana, A., Poojary, S., ... & Kaushal, V. (2020). Indian association of dermatologists, venereologists and leprologists (IADVL) task force against recalcitrant tinea (ITART) consensus on the management of glabrous tinea (INTACT). Indian Dermatology Online Journal, 11(4), 502.
Sharma, R., Gupta, R., & Malhotra, P. (2019). Topical sertaconazole vs topical terbinafine for treatment of Tinea corporis and Tinea cruris. Journal of Advanced Medical and Dental Sciences Research, 7(8), 297–300.
Sonego, B., Corio, A., Mazzoletti, V., Zerbato, V., Benini, A., Di Meo, N., Zalaudek, I., Stinco, G., Errichetti, E., & Zelin, E. (2024). Trichophyton indotineae, an emerging drug-resistant dermatophyte: A review of the treatment options. Journal of Clinical Medicine, 13(12), 3558. https://doi.org/10.3390/jcm13123558
Soni, M. (2017). Effectiveness and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris. Journal of Advanced Medical and Dental Sciences Research, 5(4), 132–134.
Ständer, S., Metz, M., Ramos, M. H. F., Maurer, M., Schoepke, N., Tsianakas, A., Zeidler, C., & Luger, T. A. (2016). Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: A prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability. Acta Dermato-Venereologica, 96(6), 792–796. https://doi.org/10.2340/00015555-2268
Sumyuktha, J., Narasimhan, M., & Ahamed, P. B. (2017). A comparative trial between the therapeutic efficacy of topical 2% sertaconazole cream and 1% terbinafine cream in the treatment of tinea cruris/tinea corporis. International Journal of Research in Dermatology, 3(1), 59–63. 10.18203/issn.2455-4529.IntJResDermatol20170082
Tufanaru, C., Munn, Z., Aromataris, E., Campbell, J., & Hopp, L. (2020). Chapter 3: Systematic reviews of effectiveness. In E. Aromataris & Z. Munn (Eds.), JBI manual for evidence synthesis. JBI. https://doi.org/10.46658/JBIMES-20-04
World Health Organization. (2022). WHO fungal priority pathogens list to guide research, development and public health action. World Health Organization. https://www.who.int/publications/i/item/9789240060241
License
Copyright (c) 2026 Ni Luh Putu Eka Widya Ananta Putri, Marisa Syavitri Dilaga
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
